AAAAAA

   
Results: 1-11 |
Results: 11
ACTG (AIDS Clinical Trials Group) 384: A strategy trial comparing consecutive treatments for HIV-1
Authors: Smeaton, LM DeGruttola, V Robbins, GK Shafer, RW
Citation: Lm. Smeaton et al., ACTG (AIDS Clinical Trials Group) 384: A strategy trial comparing consecutive treatments for HIV-1, CONTR CL TR, 22(2), 2001, pp. 142-159
Virologic and regimen termination surrogate end points in AIDS clinical trials
Authors: Gilbert, PB DeGruttola, V Hammer, SM Kuritzkes, DR
Citation: Pb. Gilbert et al., Virologic and regimen termination surrogate end points in AIDS clinical trials, J AM MED A, 285(6), 2001, pp. 777-784
A model for markers and latent health status
Authors: Lee, MLT DeGruttola, V Schoenfeld, D
Citation: Mlt. Lee et al., A model for markers and latent health status, J ROY STA B, 62, 2000, pp. 747-762
The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan
Authors: DeGruttola, V Dix, L D'Aquila, R Holder, D Phillips, A Ait-Khaled, M Baxter, J Clevenbergh, P Hammer, S Harrigan, R Katzenstein, D Lanier, R Miller, M Para, M Yerly, S Zolopa, A Murray, J Patick, A Miller, V Castillo, S Pedneault, L Mellors, J
Citation: V. Degruttola et al., The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan, ANTIVIR TH, 5(1), 2000, pp. 41-48
Both serum HIV type 1 RNA levels and CD4(+) lymphocyte counts predict clinical outcome in HIV type 1-infected subjects with 200 to 500 CD4(+) cells per cubic millimeter
Authors: Kim, S Hughes, MD Hammer, SM Jackson, JB DeGruttola, V Katzenstein, DA
Citation: S. Kim et al., Both serum HIV type 1 RNA levels and CD4(+) lymphocyte counts predict clinical outcome in HIV type 1-infected subjects with 200 to 500 CD4(+) cells per cubic millimeter, AIDS RES H, 16(7), 2000, pp. 645-653
Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: A meta-analysis
Authors: Babiker, A Bartlett, J Breckenridge, A Collins, G Coombs, R Cooper, D Creagh, T Cross, A Daniels, M Darbyshire, J Dawson, D DeGruttola, V DeMasi, R Dolin, R Eron, J Fischl, M Grossberg, S Hamilton, J Hammer, S Hartigan, P Henry, K Hill, A Hughes, M Kahn, J Katlama, C Katzenstein, D Kim, S Mildvan, D Montaner, J Moore, M Neaton, J O'Brien, W Ribaudo, H Richman, D Saag, M Salgo, M Saravolatz, L Schooley, R Seligmann, M Staszewski, S Struthers, L Tierney, C Tsiatis, A Welles, S
Citation: A. Babiker et al., Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: A meta-analysis, AIDS RES H, 16(12), 2000, pp. 1123-1133
Beta-blockade for patients undergoing vascular surgery
Authors: Litwack, RS Gilligan, DM DeGruttola, V
Citation: Rs. Litwack et al., Beta-blockade for patients undergoing vascular surgery, N ENG J MED, 342(14), 2000, pp. 1052-1052
Methods for investigation of the relationship between drug-susceptibility phenotype and human immunodeficiency virus type 1 genotype with applications to AIDS Clinical Trials Group 333
Authors: Sevin, AD DeGruttola, V Nijhuis, M Schapiro, JM Foulkes, AS Para, MF Boucher, CAB
Citation: Ad. Sevin et al., Methods for investigation of the relationship between drug-susceptibility phenotype and human immunodeficiency virus type 1 genotype with applications to AIDS Clinical Trials Group 333, J INFEC DIS, 182(1), 2000, pp. 59-67
Clinical trials using HIV-1 RNA-based primary endpoints: Statistical analysis and potential biases
Authors: Marschner, IC Betensky, RA DeGruttola, V Hammer, SM Kuritzkes, DR
Citation: Ic. Marschner et al., Clinical trials using HIV-1 RNA-based primary endpoints: Statistical analysis and potential biases, J ACQ IMM D, 20(3), 1999, pp. 220-227
Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection:meta-analyses of the randomised evidence
Authors: Abrams, D Allan, D Antunes, F Breckenridge, A Bruun, J Cameron, W Carbon, C Chalmers, I Chang, H Chodakewitz, J Clendenin, N Clumeck, N Collier, A Collins, G Cooper, E Cooper, D Danner, S D'Aquila, R DeGruttola, V DeMasi, R Dee, L Deyton, L Dixon, D Farthing, C Feinberg, J Fischl, M Flepp, M Gartland, M Gatell, J Gazzard, B Goebel, F Gotzsche, P Gringeri, A Hall, D Hamilton, J Hammer, S Hartigan, P Heath-Chiozzi, M Henry, K Hill, A Hirschel, B Ioannidis, J Kahn, J Katlama, C Katzenstein, D Killen, J King, E de Loes, SK Kravcik, S Lange, J Leavitt, R Leonard, J Maeland, A Mannucci, P Mathiesen, L McDade, H Meibohn, A Melander, H Merigan, T Mulder, J Myers, M Neaton, J Nessling, M Perrin, L Pettinelli, C Phair, J Phillips, A Pinching, A Poppa, A Power, L Reiss, P Richman, D Rooney, J Rousseau, F Rutherford, G Salgo, M Sandstrom, E Saravolatz, L Savidge, G Schnittman, S Schooley, R Seligmann, M Simberkoff, M Skowron, G Slade, P Smith, D Smith, RP Soriano, V Stanley, K Stingl, G Stoffels, P Struthers, L Tierney, C Thompson, M Van der Broeck, R Van Leeuven, R Van Weverling, G Veenstra, J Vella, S Volberding, P Weber, J Winslow, D Yeni, P Yeo, J Dormont, J Sande, M Weller, I Babiker, A Collins, R Darbyshire, J Duncan, W Foulkes, M Hughes, M Peto, R Peto, T Walker, S
Citation: D. Abrams et al., Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection:meta-analyses of the randomised evidence, LANCET, 353(9169), 1999, pp. 2014-2025
Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection
Authors: Murphy, RL Gulick, RM DeGruttola, V D'Aquila, RT Eron, JJ Sommadossi, JP Currier, JS Smeaton, L Frank, I Caliendo, AM Gerber, JG Tung, R Kuritzkes, DR
Citation: Rl. Murphy et al., Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection, J INFEC DIS, 179(4), 1999, pp. 808-816
Risultati: 1-11 |